NAFL

Valbiotis Publishes Its 2022 Annual Results and Provides an Update on Its Strategic Roadmap

Retrieved on: 
Wednesday, March 15, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Fitness & Nutrition, Clinical Trials, United Nations Global Compact, Statutory auditor, Corporate social responsibility, ISO, PEA, Risk, AASLD, Partnership, Prediabetes, Research and development, Liver, Dyslipidemia, LDL, Université Laval, NASH, NAFL, Hypercholesterolemia, Phase, Patient, Type 2 diabetes, ASM Clermont Auvergne, De novo, Hepatology, INAF, CHF, INSIGHT, American Association of Clinical Endocrinologists, Development, Marketing, CSR, Volunteering, ANR, University, Food court, R, Pharmaceutical industry, Cryptocurrency

Sébastien PELTIER, Chairman of the Board of Directors at Valbiotis, comments: "During the year 2022, Valbiotis continued to pursue its R&D roadmap while providing itself with the means to accelerate its commercial strategy.

Key Points: 
  • Sébastien PELTIER, Chairman of the Board of Directors at Valbiotis, comments: "During the year 2022, Valbiotis continued to pursue its R&D roadmap while providing itself with the means to accelerate its commercial strategy.
  • The year 2022 was marked by the positive results of the Phase II HEART study, announced in June ( press release of June 13, 2022 ).
  • Regarding TOTUM•854, Valbiotis launched the Phase II/III INSIGHT and INSIGHT 2 clinical studies in early 2022 ( press release of February 17, 2022 ).
  • At the beginning of 2022, Valbiotis updated the development strategy for TOTUM•448 ( press release of January 6, 2022 ).

Valbiotis Announces Positive Results in the Bioavailability and Mode of Action TOTUM•854 Clinical Study, Against High Blood Pressure

Retrieved on: 
Monday, January 30, 2023
Health, Clinical Trials, Research, Science, Pharmaceutical, Cardiology, Biotechnology, NOX2, Lipid, Cell, Oxidative stress, AMF, INSIGHT, Phase, Metabolomics, Radical, DSM-IV codes, American Heart Association, European Society of Cardiology, Executive Committee, Risk, Volunteering, Blood pressure, PEA, Human, Blood, Fibrinogen, BPI, Endothelium, NAFL, European Regional Development Fund, ERDF, White, Serum, Cardiovascular disease, Research and development, AHA, Development, Translational research, Metabolism, Inflammation, MCP-1, ESC, Discovery, Hypertension, Popular Executive Committee of Valencia, Disease, European, Pharmaceutical industry, Dietary supplement, Europe 1

Damage to the vascular wall is a major mechanism in the progression of high blood pressure.

Key Points: 
  • Damage to the vascular wall is a major mechanism in the progression of high blood pressure.
  • This first-in-human evidence confirms the relevance of TOTUM•854's positioning in the early stages of the disease and bodes well for the ongoing Phase II/III clinical efficacy studies in high blood pressure."
  • Mode of action tests also revealed a reduction in angiotensin I-converting enzyme (ACE1) activity, an enzyme well known in the pathophysiology of high blood pressure.
  • 3The fraction of blood remaining after all blood cells (red blood cells, leukocytes, platelets) and fibrinogen (a protein involved in coagulation) have been removed.

Valbiotis Announces the Signature of a Research Partnership in Intestinal Microbiota With the MEDIS Unit From the Clermont Auvergne University

Retrieved on: 
Wednesday, December 14, 2022
Cardiology, Biotechnology, Alternative Medicine, Other Health, Health, Other Natural Resources, Pharmaceutical, Other Science, Natural Resources, Research, Science, Stomach, Thermoregulation, European Regional Development Fund, Research, PH, Professor, Microbiology, Dysbiosis, Clermont Auvergne University, Risk, Research and development, Development, Lipid, Union, Partnership, PEA, Digestion, Gastrointestinal tract, Human, Culture, Food, R, United Nations Research Institute for Social Development, Kinetics, Colon, NAFL, Bolam v Friern Hospital Management Committee, UCA, Absorption, Atherosclerosis, Carbohydrate, Institut national de la recherche agronomique, BPI, Ufuk Esin, Water, Degenerative disease, Dyslipidemia, Cirrhosis, Microbiota, Patient, Translational research, NASH, D, ERDF, Environment, AMF, Lipid metabolism, Dietary supplement, Pharmaceutical industry, Feed manufacturing, Health

This is an innovative angle, in line with our research and development strategy.

Key Points: 
  • This is an innovative angle, in line with our research and development strategy.
  • The MIMETiv project, which will benefit from the combined expertise of the MEDIS Unit and Valbiotis, will take place in two stages.
  • Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time.
  • 1MIMETiv: Microbiote intestinal et maladies mtaboliques chez lHomme (Intestinal microbiota and metabolic diseases in humans): a unique in vitro digestive system to catalyze the development of innovative nutritional strategies.

deCODE genetics publishes multiomics study of nonalcoholic fatty liver disease

Retrieved on: 
Monday, October 24, 2022
Sequence, Proteomics, Plasma, Disease, BMI, GPAM, NAFLD, Magnetic resonance imaging, NAFL, Patient, Hepatocellular carcinoma, Fatty liver disease, HIV disease progression rates, HCC, Risk, NASH, Cirrhosis, Liver, Genome-wide association study, Protein, Genetics, Genetic distance, Icelandic, Biomarker, Nature Genetics, Dietary supplement, Medical device, Medical imaging, Amgen

REYKJAVIK, Iceland, Oct. 24, 2022 /PRNewswire/ -- Scientists at deCODE genetics, a subsidiary of Amgen, publish today a large genome-wide association study on nonalcoholic fatty liver disease (NAFLD) in Nature Genetics.

Key Points: 
  • Scientists at deCODE genetics in Iceland have discovered rare, protective loss-of-function variants that point to potential drug targets fornonalcoholic fatty liver disease (NAFLD).
  • REYKJAVIK, Iceland, Oct. 24, 2022 /PRNewswire/ -- Scientists at deCODE genetics, a subsidiary of Amgen, publish today a large genome-wide association study on nonalcoholic fatty liver disease (NAFLD) in Nature Genetics.
  • Nonalcoholic fatty liver (NAFL), when over 5% of the liver is fat with no identifiable causes such as excessive alcohol consumption, is the first stage of NAFLD.
  • NAFL can progress to non-alcoholic steato-hepatitis (NASH) which can progress further into liver cirrhosis and hepatocellular carcinoma (HCC).

deCODE genetics publishes multiomics study of nonalcoholic fatty liver disease

Retrieved on: 
Monday, October 24, 2022
Sequence, Proteomics, Plasma, Disease, BMI, GPAM, NAFLD, Magnetic resonance imaging, NAFL, Patient, Hepatocellular carcinoma, Fatty liver disease, HIV disease progression rates, HCC, Risk, NASH, Cirrhosis, Liver, Genome-wide association study, Protein, Genetics, Genetic distance, Icelandic, Biomarker, Nature Genetics, Dietary supplement, Medical device, Medical imaging, Amgen

REYKJAVIK, Iceland, Oct. 24, 2022 /PRNewswire/ -- Scientists at deCODE genetics, a subsidiary of Amgen, publish today a large genome-wide association study on nonalcoholic fatty liver disease (NAFLD) in Nature Genetics.

Key Points: 
  • Scientists at deCODE genetics in Iceland have discovered rare, protective loss-of-function variants that point to potential drug targets fornonalcoholic fatty liver disease (NAFLD).
  • REYKJAVIK, Iceland, Oct. 24, 2022 /PRNewswire/ -- Scientists at deCODE genetics, a subsidiary of Amgen, publish today a large genome-wide association study on nonalcoholic fatty liver disease (NAFLD) in Nature Genetics.
  • Nonalcoholic fatty liver (NAFL), when over 5% of the liver is fat with no identifiable causes such as excessive alcohol consumption, is the first stage of NAFLD.
  • NAFL can progress to non-alcoholic steato-hepatitis (NASH) which can progress further into liver cirrhosis and hepatocellular carcinoma (HCC).

Valbiotis Accelerates Its Marketing Strategy

Retrieved on: 
Friday, October 7, 2022
Biotechnology, Pharmaceutical, Health, Cardiology, Union, AMF, Risk, Development, AEC, ERDF, Growth, European Regional Development Fund, Pharmacy, NAFL, Lists of diseases, Research and development, Patient, Investor, LDL, Cropping system, Research, TOTUM, Blood pressure, PEA, Partnership, NASH, IFREMER, Company, Marketing, Pathology, TOP, IFOP, Prediabetes, BPI, Medicine, Pharmacist, Degenerative disease, DNA, Heart, Practitioner, Solution, Pharmaceutical industry, Dietary supplement, Aquaculture

Valbiotis (FR0013254851 ALVAL, PEA / SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, is accelerating its marketing strategy.

Key Points: 
  • Valbiotis (FR0013254851 ALVAL, PEA / SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, is accelerating its marketing strategy.
  • At the same time, consumers/patients will be targeted directly through an adapted digital marketing strategy.
  • For more information about Valbiotis, please visit: www.valbiotis.com
    This press release contains forward-looking statements about Valbiotis objectives.
  • Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time.

Valbiotis - Increased Momentum in the Clinical Newsflow for Major Indications: Results Expected in 2022 for Prediabetes, Hypercholesterolemia and High Blood Pressure

Retrieved on: 
Thursday, January 6, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Time, Trial of the century, NASH, Type 2 diabetes, Non-alcoholic fatty liver disease, Industrial Affairs Committee (Iceland), Hypercholesterolemia, Development, ERDF, Research and development, Director, AMF, Company, Patient, Blood pressure, DNA, Calendar, Fatty liver disease, Phase, Institute, INAF, European Regional Development Fund, Lists of diseases, NAFL, CEO, Volunteering, Research, Prediabetes, Food science, Partnership, Degenerative disease, Population, Board, Union, Risk, Investor, Université Laval, Heart, BPI, Nutrition, Pharmaceutical industry, Medical imaging, Health insurance, Medical device

Clinical results regarding three active substances in the portfolio will become available and will be key for the launch of these substances on the prediabetes, hypercholesterolemia and high blood pressure markets.

Key Points: 
  • Clinical results regarding three active substances in the portfolio will become available and will be key for the launch of these substances on the prediabetes, hypercholesterolemia and high blood pressure markets.
  • The clinical study results calendar announced for 2022 complies with the development plans adopted for Valbiotis active substances.
  • Details on the clinical results expected in 2022 are as follows:
    The results of the pivotal Phase II/III REVERSE-IT study on TOTUM63 should be available by the end of 20222.
  • Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time.

180 Life Sciences Corp. Enters into a License Agreement with University of Oxford for Regenerative Molecule HMGB1 for Liver Diseases

Retrieved on: 
Wednesday, December 15, 2021
Investigational New Drug, U.S. Securities and Exchange Commission, NAFLD, Form, List of life sciences, Stanford University, Eleazar Sukenik, Company, Good manufacturing practice, Fatty liver disease, Pain, Hebrew University of Jerusalem, Non-alcoholic fatty liver disease, Population, Cirrhosis, Life, Growth, Adult, Liver, Private Securities Litigation Reform Act, NASH, IND, Disease, M.E, Immunosuppression, NASDAQ, Risk, HMGB1, Liver transplantation, PALO, Nasdaq, File, CEO, Research, Safety, Inflammation, Patient, Mortality, Therapy, Achievement, Tissue, Drug development, University, Security (finance), Regeneration, Program, GLOBE, Hepatocellular carcinoma, GMP, Fibrosis, University of Oxford, NAFL, Western world, Behavior, Pharmaceutical industry, Dietary supplement

There is currently no approved therapeutic for limiting damage and fibrosis in patients with liver disorders such as Non-Alcoholic Steatohepatitis (NASH).

Key Points: 
  • There is currently no approved therapeutic for limiting damage and fibrosis in patients with liver disorders such as Non-Alcoholic Steatohepatitis (NASH).
  • 180 Life Sciences, through a collaboration led by Professor Jagdeep Nanchahal at the University of Oxford, is pursuing a program to identify novel therapeutic targets.
  • Dr. James Woody, CEO of 180 Life Sciences, commented, Liver diseases represent a large unmet medical need.
  • 180 Life Sciences is leading the research into solving one of the worlds biggest drivers of disease inflammation.

IV BioHoldings Debuts Liquid Biopsy Portfolio; Partners with P4 Diagnostix to Scale Commercialization of Non-Invasive Lung, Liver and Breast Diagnostics

Retrieved on: 
Wednesday, September 22, 2021
Biotechnology, General Health, Other Health, Health, Oncology, Blood, Efficiency, Explainable artificial intelligence, Non-alcoholic fatty liver disease, Saliva, Entrepreneurship, EHR, Â, Pathology, Informatics, Laboratory, Liquid biopsy, Breast cancer, Industry, Classification, Lung, NAFL, Behavior, Health, IV, NAFLD, IP, NASH, CEO, Disease, Science, Technology, Lists of diseases, Fatty liver disease, Clinical trial, Partnership, Molecular medicine, Solution, Woman, Risk, Liver, Agnostic (data), R, Ecosystem, Intellectual property, Time, LBS, Degenerative disease, Diagnosis, CLIA, Patient, Biology, Lung cancer, Research, Drug development, Data analysis, Time-invariant system, Medical imaging, Fine chemical, Medical device, IV BioHoldings, P4 Diagnostix®, Liquid Biosciences, IV BIOHOLDINGS, P4 DIAGNOSTIX®, LIQUID BIOSCIENCES

Collectively, the IVBH companies comprise eight clinical-ready diagnostics, spanning the care continuum for lung cancer, non-alcoholic fatty liver disease (NAFLD) and breast cancer, respectively.

Key Points: 
  • Collectively, the IVBH companies comprise eight clinical-ready diagnostics, spanning the care continuum for lung cancer, non-alcoholic fatty liver disease (NAFLD) and breast cancer, respectively.
  • IVBH is now scaling to support its flagship lung, liver and breast programs through clinical development and commercialization.
  • We are a bio innovation studio specializing in de novo company creation at the intersection of diagnostics and life sciences.
  • P4 is made up of these industry-leading companies: Theranostix, Long Island Pathology, Platinum Pathology, Metamark Laboratories and P4 Clinical.